Compass Therapeutics Inc [CMPX] stock is trading at $2.00, down -0.50%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CMPX shares have gain 18.34% over the last week, with a monthly amount glided 17.99%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Compass Therapeutics Inc [NASDAQ: CMPX] stock has seen the most recent analyst activity on April 02, 2025, when Leerink Partners upgraded its rating to a Outperform but kept the price target unchanged to $6 for it. Previously, Guggenheim started tracking the stock with Buy rating on February 24, 2025, and set its price target to $12. On February 19, 2025, Piper Sandler initiated with a Overweight rating and assigned a price target of $12 on the stock. D. Boral Capital started tracking the stock assigning a Buy rating and suggested a price target of $32 on December 23, 2024. Leerink Partners downgraded its rating to a Market Perform and reduced its price target to $4 on November 15, 2024. Ladenburg Thalmann upgraded its rating to Buy for this stock on September 16, 2024, but kept the price target unchanged to $5. In a note dated January 31, 2023, Jefferies initiated an Buy rating and provided a target price of $8 on this stock.
Compass Therapeutics Inc [CMPX] stock has fluctuated between $0.76 and $4.08 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Compass Therapeutics Inc [NASDAQ: CMPX] shares were valued at $2.00 at the most recent close of the market. An investor can expect a potential return of 200.0% based on the average CMPX price forecast.
Analyzing the CMPX fundamentals
Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -15.01%, Pretax Profit Margin comes in at -12.93%, and Net Profit Margin reading is -12.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.32 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.87 points at the first support level, and at 1.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.11, and for the 2nd resistance point, it is at 2.21.
Ratios To Look Out For
For context, Compass Therapeutics Inc’s Current Ratio is 8.33. Also, the Quick Ratio is 8.33, while the Cash Ratio stands at 8.3. Considering the valuation of this stock, the price to sales ratio is 325.37, the price to book ratio is 2.51.
Transactions by insiders
Recent insider trading involved GORDON CARL L, Director, that happened on Apr 09 ’25 when 3.57 million shares were sold. Director, ORBIMED ADVISORS LLC completed a deal on Apr 09 ’25 to sell 3.57 million shares. Meanwhile, Director OrbiMed Genesis Master Fund, L bought 3.57 million shares on Apr 09 ’25.
